Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
← catalyst calendarSponsored by Cumberland Pharmaceuticals (industry) · CPIX — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
34estimated
Sites
13
Countries
India, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jan 2017 | actual | When the study began enrolling |
| Primary completion | Jun 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2016-02-15 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Scleroderma, Diffuse
- Scleroderma, Systemic
- Scleroderma, Limited
- Sclerosis, Progressive Systemic
- Skin Diseases
- Connective Tissue Diseases
- Pathologic Processes
- Autoimmune Diseases
Interventions
- Drug: Oral Ifetroban — also filed as Ifetroban
- Drug: Oral Placebo — also filed as Ifetroban
Primary outcome
what the primary-completion date above is the date OFIncidence of adverse events (AEs) and Serious AEs (SAEs)
measured 56 weeks
Permalink · CPIX's whole pipeline · Catalyst calendar · Every registered study · What changed